Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACI-24 in Adults With Down Syndrome
NCT02738450Phase 1Completed
- Sponsor
- AC Immune SA
- Start
- Mar 2016
- Primary completion
- Jun 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ACI-24 in Down syndrome (3 arms), sponsored by AC Immune SA. Primary endpoint: Antibody Titer (Serum Anti-Aβ1-42 Free IgG) at Week 50. Started Mar 2016; status: completed.
02
Drugs
ACI-24
03
Conditions
Down syndrome
Beyond the preview
Go deeper on NCT02738450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02738450.